Candid Therapeutics Plans to Initiate Multiple Phase 2 Studies Following Promising Clinical Data of T-cell Engagers in Autoimmune Diseases
T-cell engagers (TCEs) have the most promising product profile across all deep B-cell depleting modalities Cizutamig (BCMA TCE) positioned as first and best-in-class for autoimmune diseases Over 60 patients with autoimmune diseases dosed with cizutamig and CND261 (CD20 TCE) bringing total clinical experience inclusive of oncology to nearly 200 patients San Diego, CA, January 8, […]
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
– First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated Q3 2026 – – Third dose cohort initiated in Phase 1 trial of ALX 2004; study remains on track to provide initial safety data in 1H 2026 […]
Alumis Announces Pricing of Upsized Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the pricing of an upsized underwritten public offering of 17,650,000 shares of its common stock at a price to the public of $17.00 per share. The […]
Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development Across a Broad Range of Tumors and Advance Pioneering Pipeline and Helicon Platform
Financing co-led by RA Capital Management, Fidelity Management & Research Company, and Janus Henderson Investors CAMBRIDGE, Mass., January 8, 2026 — Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer using its Helicon TM peptide platform to drug historically undruggable targets, today announced the successful closing of a […]